There are currently 428 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT03400215
Recruiting
The role of fat in breast cancer development and growth has been studied extensively using body mass index, a measure of whole body fatness, and dietary fat intake in a number of epidemiological studies. However, there is a paucity of studies, on an individual level, to assess the role of breast fat itself in breast cancer due to lack of a non-invasive and fast measurement method. Since breast fibroglandular cells are surrounded by breast fat cells, the characteristics of breast fat may have a s... Read More
Gender:
FEMALE
Ages:
Between 25 years and 99 years
Trial Updated:
03/31/2025
Locations: NYU Langone Health, New York, New York
Conditions: Breast Cancer
Register for Updates
Improving Care After Inherited Cancer Testing
NCT04763915
Recruiting
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Register for Updates
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: HonorHealth Research Institute, Phoenix, Arizona +26 locations
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
Register for Updates
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT05095207
Recruiting
This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/28/2025
Locations: Mount Sinai Beth Israel, New York, New York +2 locations
Conditions: Breast Cancer, Metastasis
Register for Updates
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT04119024
Recruiting
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, gr... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Metastatic Melanoma, Metastatic Malignant Solid Neoplasm, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Register for Updates
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT04711824
Recruiting
This study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers. This study will have a Phase I portion in which subjects will be enrolled based on 3+3 dose escalation rules. Three dose levels of olaparib will be studied. Cycle 1 of study treatment will consist of Olaparib given twice daily concurrently wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Breast Cancer, Brain Metastases, Adult
Register for Updates
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT05535192
Recruiting
This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
03/26/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer
Register for Updates
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT05150652
Recruiting
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/25/2025
Locations: University of Kentucky Markey Cancer Center, Lexington, Kentucky
Conditions: Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
Register for Updates
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT05483491
Recruiting
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Register for Updates
Longitudinal Sexual and Reproductive Health Study of Women with Breast Cancer and Lymphoma
NCT01788839
Recruiting
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Register for Updates
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT06169371
Recruiting
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Illinois, Chicago, Illinois +1 locations
Conditions: Breast Cancer
Register for Updates
MRg-NIRS Imaging System Breast Cancer Trial
NCT06400563
Recruiting
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
Gender:
FEMALE
Ages:
Between 18 years and 83 years
Trial Updated:
03/24/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Breast Cancer
Register for Updates